Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, when your company is run by felons, fails its trial, and takes on convertible debt because it's broke, that tends to happen.
But I guess you have unsubstantiated rumors on social media to keep you going...lol.
I think you’re safe to expect late April application, mid to late May approval.
Probably late April application.
Was it the failed trial that impressed you? Lol.
“A marvel of a molecule.” Fails its trial.
It’s possible, but people sit on multiple boards.
Yes, the offering is closed.
Why wasn't it PRed? Who knows?
Why would people sell right now? Who knows?
Can we just fast-forward a few months please?
Hit what nerve?
One drug passed its trial easily, one didn’t.
One company ran by accomplished executives, one by a felon.
One drug will get an EUA, one won’t.
Anyone pushing leronlifail or CYDY is trash. End of story.
Hey, quick question, did leronlifail fail it’s last trial?
Oh it did? Oh, it’s stupid to pay up for a failed drug that can’t get an EUA in America?
Get back to me when CYDY isn’t run by a felon and pitching trash drugs.
The FDA ignores anecdotal evidence because it's....anecdotal.
Maybe they should consider passing an actual trial designed to remove...anecdotal evidence.
Remind me, did they pass their trial, or did they pick a handful of data points because it was the only thing they could salvage?
Of course, on this board, convertible notes mean nothing. Failing a trial means nothing. Ad-hoc sample size of N~60 means nothing after failing said trial. Lawsuits and felony charges don't matter.
Man, glad 1 person might have gotten better in the Philippines. That'll get that FDA attention.
To clarify, that's 3.5 million shares worth up to $1 billion.
It's about time. This is transform your core business cash, and is barely a drop in the bucket to the float.
Any news of a potential buyout will be after an EUA is granted. Until then, it’s too risky to plunk down billions for a drug that might not be granted.
Now, we here know this is a slam dunk EUA, but that’s not how businesses operate. They’ll wait for it to materialize.
To be granted a EUA, we had to have more than $200 million to pay upfront manufacturing to satisfy the 100k doses requirement.
At this point I hope we sell out to McDonalds and have Lenz come free with every Happy Meal.
I'm sure those shares are hotter than we expect.
They extremely cherry-picked data points and have essentially lied.
If loserlimab saves so many lives, why did it fail its own trial?
Why did they have to cherry-pick N=61 data points to try and salvage a PR?
Why did they selectively hype one 14 day period and ignore the other?
Sure is a weird way to go about getting an EUA. I figure just passing a trial would be WAY easier.
This is the only thought that makes sense. Anything else implies a cash grab, which is contrary to the moves made to this point.
True, I could just be melodramatic. I’m just tired of the same song and dance.
Oh we’re going right back down to $18.50 and below.
Shorts are going to absolutely demolish this after those shares are sold at $18.50.
What it does is trap you and forces you to hold on for positive news, because the alternative will be panic selling.
In the OTC, t-trades are generally shares being created via conversion vehicles.
Any company on the verge of bankruptcy and a failed product will start to see them.
HGEN did provide the exclusion criteria, and he’s full of shit.
They excluded 33 people that did not receive the full dosage, or weren’t observed to have received the full dosage.
He basically tweeted an “Oopsie” after that.
Ignored.
Take your neighbors with you on the way out. Remove the taint you’re leaving behind.
Their shit analyst harped on mITT, and ultimately thinks the data is overrated because...he doesn’t get the differences from other mabs.
HGEN will publish secondary endpoints later, and probably all trial criteria and controls as well.
EUA is coming.
Why are you still alive? You bring no value to anything or anyone.
Meh, now that the results are good, the focus has shifted with mITT instead of iTT.
Basically, 33 patients were excluded from the study due to disqualifying factors, just like many studies have done, only now it's a HUGE deal for HGEN for....reasons.
Oh well. Just another HGEN day.
Lol, "narrowly", "could have tipped", etc.
Sorry you keep investing in OTHER biotechs that fail.
This one succeeded, despite what "might have happened".
Next.
Lol, thanks! Unfortunately, as this is HGEN, it must suffer even with the best of news to trudge uphill.
Oh well, EUA by May. That's the next hurdle.
Never worried for one second....rofl!
How can you own CYDY and talk about anyone else failing?
Oh right, you were dumb enough to invest in CYDY.
Good thing HGEN hasn’t failed a trial. That’d be embarrassing, and I certainly wouldn’t talk trash to my betters.
Fantastic multipoint summary,
Well done!
He’s butthurt that CYDY is an obvious scam and yet he can’t bring himself to admit it.
Oh well, others will take his money and enjoy.
Man, it just suck to invest in trash like CYDY. I can’t imagine being that stupid.
Imagine a company ran by a felon, failing their trial completely, and STILL being invested.
Truly stupid.
Hilarious for you to talk about trials.
CYDY FAILED. END OF STORY.
HGEN will pass their primary endpoint. I can’t speak to secondary, but I hope at least a couple there as well.
What a joke you guys are.
Obviously you're a friend of the board, and a welcome poster.
But to say that CYDY hit any endpoint for any demographic is not only misleading, but fuels the typical "OTC Investor" conspiracy nonsense that plagues the industry.
They're welcome to design a new trial and show efficacy for that demographic, but they don't get to pick a subset of the data and say "Mission Accomplished!", which they tried to soft-peddle in their scam PRs.
You mean the cherry-picked trial results?
Leronlimab DIDN'T meet its primary endpoint for any demographic, period. There isn't enough data for any subset demographic to be singled out as successful.
To say otherwise is speculative nonsense, and is the same trash I'd expect on the CYDY board.
In the OTC, it’s often a sign of dumping shares. To suggest otherwise is either ignorance, denial, or intentional lying.
Shocking that would happen on THIS board...rofl!
Your argument is the stock price now?
Yep, stock goes down, the data MUST be terrible.
Stock goes up, must be a scam and any day now the TERRIBLE data will come out.
Once again, go fuck yourself.
A major short attack (with follow up) that also lead to some retail bleeding.
This is part of my major issue with how shorting is implemented; while there can be substantial risk, institutions and large private players can short so much at one time that it creates a massive fear-based sell-off.
It's a self-fulfilling prophecy at that point. They'll eventually cover and the resulting large buy will signal the "recovery" that shouldn't have been necessary in the first place.
Over the long term it isn't that important, but as investment timeframes have shortened, the effects of shorting are dramatically exaggerated.
It’s a few smart people and the rest are comic relief (barely).
Typical lazy investor. You bought on hype and haven’t bothered to do any real research.
At least someone else will enjoy the $100 bucks you scraped together to buy this garbage.
You mean the emails going right into the trash. Guess what? Doctors with a vested interest in profiting off drugs that fail trials aren’t taken seriously.
Pathetic.